Biogen (BIIB) vs GSK (GSK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biogen (BIIB) has outperformed GSK (GSK) over the past year, gaining 44.7% versus a gain of 7.4%. Over five years, GSK leads with a +19.3% price change compared with -22.3% for BIIB. GSK is the larger company by market cap ($93.16 billion vs $33.35 billion), about 2.8 times the size.
On valuation, GSK trades at a lower forward P/E (9.4x vs 13.6x for Biogen). GSK pays a dividend yielding 1.46%, while Biogen does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIIB | GSK |
|---|---|---|
| Share price | $225.71 | $46.50 |
| Market cap | $33.35B | $93.16B |
| 1-day change | +3.33% | -0.09% |
| YTD return | +24.12% | -5.10% |
| 1-year return | +44.68% | +7.36% |
| 5-year return | -22.32% | +19.30% |
| P/E ratio (TTM) | 40.09 | 14.67 |
| Forward P/E | 13.65 | 9.41 |
| EPS (TTM) | $5.63 | $3.17 |
| Dividend yield | 0.00% | 1.46% |
| Annual dividend | $0.00 | $0.68 |
| Revenue (latest FY) | $9.89B | — |
| Revenue growth (YoY) | +2.22% | — |
| Net income (latest FY) | $1.29B | — |
| Gross margin | 75.69% | — |
| Net margin | 13.07% | — |
| 52-week high | $230.49 | $61.70 |
| 52-week low | $138.00 | $42.85 |
| Distance from 52-week high | -2.07% | -24.64% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +5.52% | +27.59% |
| Average volume | 1.06M | 3.85M |
| Shares outstanding | 147.75M | 2.00B |
| Employees | 7,500 | 66,841 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GSK is about 2.8 times larger than Biogen by market value ($93.16B vs $33.35B).
- BIIB has outperformed GSK by 37.3 percentage points over the past year.
- Biogen trades at a higher earnings multiple (40.1x vs 14.7x trailing P/E).
- GSK offers a meaningfully higher dividend yield (1.46% vs 0.00%).
About Biogen
BIIB stock →Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,500 employees
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
BIIB vs GSK FAQ
Which is bigger, Biogen or GSK?
GSK (GSK) is larger, with a market capitalization of $93.16B compared with $33.35B for Biogen (BIIB).
Which stock has performed better over the past year, BIIB or GSK?
BIIB returned +44.68% over the past 12 months, compared with +7.36% for GSK (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIIB or GSK?
GSK has the lower trailing P/E at 14.7, versus 40.1 for BIIB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Biogen or GSK?
GSK pays a dividend yielding 1.46%, while Biogen does not currently pay a regular dividend.
Are Biogen and GSK in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Biogen and Biotechnology: Pharmaceutical Preparations for GSK.